Powered by the California Digital Library University of California to show a statistically significant reduction, drug-related hospitalizations did not. We interpret this as a matter of power; the hazard ratio point estimate for extended vs basic intervention was 0.77 for the main end point compared to 0.80 and 0.65 for drug-related hospitalization within 180 and 30 days, respectively. These figures are obviously of the same magnitude, but because there were fewer of the drug-related outcomes, they did not reach statistical significance. There are 2 counterexamples mentioned: Gillespie et al 2 and Pellegrin et al. 3 The trial by Gillespie et al 2 was considerably smaller than ours, and the apparent strong benefit for drug-related admissions (relative risk, 0.20) was offset by other admissions, so that overall readmission rates were identical in the 2 groups. The study by Pellegrin et al 3 is not randomized, but is instead a macroanalysis using interrupted time series. As we pointed out in our discussion, 1 it is conceivable that our intervention could have an effect on non-drug-related admission, as well as on drugrelated admission. For example, a patient who is hospitalized because of nonadherence would manifest as someone hospitalized because of a disease exacerbation and not necessarily because of a drug problem. If our intervention improved adherence, such hospitalization could possibly be prevented. We fully agree that it would have been desirable to present data on adherence, and we had planned to do so. Unfortunately, our adherence data were not of sufficient quality to allow for it. Van der Linden et al correctly point out that we had powered our study according a perceived risk of drug-related admissions, not general admissions as was our main outcome. We do not believe, however, this has much bearing on the interpretation of the results. Given that the estimates and their confidence intervals are known by now, little, if anything, in terms of interpretation is added by considering the presumed power at the planning stage.
In Reply Carey and Moawad, as well as Koenig and Votto, raise concerns regarding similar themes: context and policy relevance of our findings, 1 residual confounding, and whether skilled nursing facilities (SNFs) are suitable alternatives to longterm acute care hospitals (LTACs). First, we agree the use of LTACs has slightly declined in recent years partly owing to the Pathway for SGR (Sustainable Growth Rate) Reform Act of 2013 2 stipulating reduced site-neutral payment (SNP) for less sick individuals. However, SNP will not be fully implemented until 2020. 3 In the interim, LTACs will be reimbursed at a blended rate halfway between LTAC and inpatient prospective payer system rates, 3 thus making many SNP admissions still profitable.
As such, the most recent data shows that LTACs still account for over 130 000 annual admissions and $5.3 billion in annual Medicare spending, which is 18% of the spending on SNFs. 4 Furthermore, the modest decline in LTAC use among fee-for-service beneficiaries may also reflect increasing enrollment in Medicare Advantage. Release of Medicare Advantage data would greatly strengthen our understanding of postacute care.
5 Second, our findings 1 are applicable beyond 2020 when SNP will be fully implemented. We conducted another sensitivity analysis focused exclusively on the 19 539 patients who had either a prolonged intensive care unit stay or prolonged mechanical ventilation, and thus would be exempt from SNP. After adjusting for case-mix, nearly half of the variation in LTAC transfer (vs SNF) was still unrelated to patient illness severity (variation partition coefficients [VPC] for patient, hospital, and region were 54.6%, 12.4%, and 33.0%, respectively; data available on request). Third, we acknowledged in our study 1 that claims data may not fully capture differences in illness severity between patients. Thus, we have likely omitted important patient-level predictors of LTAC transfer. However, our findings of large hospital and geographic variation in LTAC use are robust to this limitation. The case-mix VPC represents the residual variation in the LTAC vs SNF transfer decision explained by unobserved differences between patients after adjusting for patient-level predictors in our model. 6 Although unobserved in our data, the case-mix VPC does in fact capture differences in cognitive status and frailty, among other severity of illness domains. Lastly, commenters questioned whether SNFs are realistic alternatives to LTACs. For the chronically critically ill requiring mechanical ventilation, the answer is mostly no. However, our study 1 shows that SNFs do substitute for LTACs for patients who are less critically ill, including many who would be exempt from SNP. While our study 1 did not attempt to distinguish appropriate vs inappropriate LTAC use, clearly what is certain is that physicians in many hospitals and regions appear comfortable using SNFs for postacute care for many patients who are similarly ill. We support the need for more research to identify which patients benefit from higher-intensity LTAC care. We hypothesize that there are patients who will be less likely to be sent to LTACs owing to SNP but nonetheless benefit from LTAC care (ie, patients with complex wounds), and vice versa, patients who are exempt from SNP but will not benefit from transfer because the 3-day minimum intensive care unit stay under SNP is an imperfect surrogate for LTAC need. 
